The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: skin rash following therapy with an immune checkpoint inhibitor
Parameters:
(1) signs and symptoms (pruritius, tenderness, burning, tightness)
(2) percent body surface area (BSA) affected
(3) activities of daily living (ADL)
|
Signs and Symptoms
|
Percent BSA
|
Activities of Daily Living
|
Grade
|
|
none or mild
|
< 10%
|
not affected
|
G1
|
|
milt to moderate
|
10-30%
|
limits instrumental ADL
|
G2
|
|
moderate to severe
|
> 30%
|
limits self-care ADL
|
G3
|
|
severe; life threatening
|
NA
|
NA
|
G4
|
The diagnosis requires exclusion of other conditions that may cause a rash.
